Intrasense, a French specialist in AI-enhanced medical imaging solutions supporting diagnosis, clinical decision-making and therapeutic monitoring ("Intrasense" or the "Company"), announces that it has received a firm and irrevocable offer from EDL for the acquisition of its Myrian® business.

Intrasense, a French expert in AI enhanced medical imaging solutions facilitating diagnosis, decision-making and therapeutic follow-up, announces that on 19 June 2026 it entered into with Guerbet a second amendment to the shareholder current account advance agreement dated 1 October 2024 for an amount of €2.4 million (the ‘Advance No. 1’) and an amendment to the
shareholder current account advance agreement dated 7 February 2025 for an amount of €5.6 million (the ‘Advance
No. 2’), in order to defer the repayment date of Advance No. 1 and Advance No. 2 from 30 June 2026 to 30 June 2027

Intrasense, a French expert in AI-enhanced medical imaging solutions facilitating diagnosis, decision-making and therapeutic follow-up, and Guerbet, a global leader in medical imaging, announce that DUOnco™ Pancreas has obtained PMDA certification in Japan under certification number 308AGBZI00003000 (Class II, Classification: Program 1 Disease Diagnostic Program, Program for X-ray imaging diagnostic device workstations (JMDN code: 40935012)). With this certification, DUOnco™ Pancreas becomes to our knowledge the first AI software focused on the pancreas to be certified in Japan.

Intrasense, a French expert in AI-powered medical imaging solutions that facilitate diagnosis, decision-making, and therapeutic follow-up, announces the publication of its 2025 annual results. These financial statements were approved by the Board of Directors on March 10, 2026.

Intrasense, French expert in AI-enhanced medical imaging solutions that facilitate diagnosis, decision-making, announces changes to the composition of its Board of Directors.

Intrasense, French expert in AI-enhanced medical imaging solutions that facilitate diagnosis, decision-making, and therapeutic follow-up, publishes its consolidated revenue for the 2025 financial year.

Munich, Germany & Montpellier, France, January 28, 2026 - Abdominal CT is one of the biggest pressure points in radiology. High volumes, long reading lists, and complex oncology follow-up cases make it challenging to ensure both accurate and timely reporting. When subtle liver, bone, or pancreatic findings remain buried in thousands of slices, small oversights can slow entire pathways. Intrasense is addressing this operational reality with DUOnco™, a suite of three standalone AI solutions co-developed with Guerbet that support earlier lesion visibility inside everyday workflows. Intrasense and deepc are partnering to make these solutions available through deepcOS®.

Intrasense, a French expert in medical imaging solutions that facilitate and secure diagnostics, decision-making, and therapeutic follow-up, announces the appointment of Mr. Stephen Armand as Chief Executive Officer of the Company.

Intrasense, French expert in medical imaging solutions to assist diagnosis, decision-making and therapeutic follow-up, confirms its financial targets for the 2025 fiscal year and updates the strategic roadmap presented in March 2025.

Intrasense, French expert in medical imaging solutions to assist and secure diagnosis, decision-making and therapeutic follow-up, announces the publication of its financial calendar for fiscal year 2026.